Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is transitioning from a development-stage biotech to a commercial-stage company, driven by the FDA approval and launch of LYMPHIR (denileukin diftitox-cxdl) for cutaneous T-cell lymphoma. The company's progress is underscored by $5.6 million in net revenue from LYMPHIR in the first six months of fiscal 2026, with gross margins around 80%. This commercial milestone provides a foundation for the company's broader strategy, which includes a late-stage pipeline targeting critical-care indications where existing treatments are limited.
LYMPHIR, approved in August 2024, is a targeted immunotherapy for adults with relapsed or refractory Stage I-III CTCL after at least one prior systemic therapy. The drug's commercial launch in December 2025 has been accompanied by strong payer coverage, with nearly 100% of covered commercial lives and 83% of targeted accounts achieving formulary inclusion or under active review as of May 2026. Beyond the initial indication, Citius is exploring LYMPHIR in combination with other therapies for gynecologic cancers and diffuse large B-cell lymphoma, with positive topline results from Phase 1 studies reported in fiscal 2026. The company has also initiated shipments to Europe, expanding its market reach.
Citius's late-stage pipeline includes Mino-Lok, an antibiotic lock solution designed to salvage central venous catheters in patients with catheter-related bloodstream infections (CRBSIs) and central line-associated bloodstream infections (CLABSIs). Currently, no FDA-approved therapy specifically targets catheter salvage, and the standard of care—catheter removal and replacement—carries risks such as pneumothorax and arterial puncture. Mino-Lok met its primary and secondary endpoints in a pivotal Phase 3 trial and has received Qualified Infectious Disease Product and Fast Track designations from the FDA. Following a Type C meeting, the company received guidance on a pathway to support a New Drug Application submission. Investor materials estimate worldwide sales potential of approximately $1.8 billion for Mino-Lok.
Another pipeline asset, Halo-Lido (CITI-002), is a proprietary topical formulation combining halobetasol and lidocaine for the symptomatic treatment of hemorrhoids. With no FDA-approved prescription products for hemorrhoids currently available, Halo-Lido could become the first, addressing a condition affecting approximately 10 million Americans annually. The company completed a Phase 2b study in 2023 and has met with the FDA to discuss next steps.
Citius is also developing a stem cell platform based on induced pluripotent stem cell-derived mesenchymal stem cells (i-MSCs) for acute respiratory distress syndrome (ARDS), including lung injury associated with sepsis. In a proof-of-concept sheep model, interim results showed improvements in oxygenation, shock, pulmonary vascular injury, and bacterial clearance compared with controls. Additional studies are planned to inform future human trials.
The company's leadership, with extensive experience in pharmaceutical development and commercialization, supports its strategic focus on assets with significant unmet medical need and differentiated commercial opportunities. With LYMPHIR generating revenue and multiple pipeline programs advancing, Citius is positioned for multiple potential catalysts across its oncology and critical-care portfolio.
